Market Overview

Surviving Mesothelioma Reports on Turkish Study Which May Help Refine Diagnostic Blood Test for Mesothelioma


New research attempts to refine the most important biomarkers for early diagnosis of the asbestos cancer.

Raleigh, NC (PRWEB) April 15, 2016

Researchers in Diyarbakir, Turkey have just released their results of tests on some of the most popular biomarkers for identifying malignant pleural mesothelioma. As Surviving Mesothelioma reports, two of the biomarkers stood out as most effective. Click here to read their full article on the research.

Dicle University scientists ran blood tests on three groups of volunteers - those with mesothelioma, those exposed to asbestos but with no mesothelioma, and healthy people with no history of exposure.

According to their article in the journal Lung, the two biomarkers with the most potential for correctly identifying malignant mesothelioma were serum mesothelin-related peptide (SMRP) and thioredoxin-1 (TRX).

"These two seem to be the most valuable biomarkers for the diagnosis of malignant pleural mesothelioma, both individually and in combination," reports lead author Melike Demir, a member of the Dicle University Faculty of Medicine.

"The search for a better, faster, more reliable way to diagnose mesothelioma is one of the most important areas of mesothelioma research, which is why we want our readers to know about these new findings," says Alex Strauss, Managing Editor of Surviving Mesothelioma.

For a more complete explanation of the Turkish research, see In Search of a Diagnostic Blood Test for Mesothelioma, now available on the Surviving Mesothelioma research.

Demir, M, et al, "Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure", March 31, 2016, Lung, Epub ahead of print,

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

For the original version on PRWeb visit:

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at